March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its portable photon-counting CT scanner for upper extremity imaging.

Designed for use in community and point-of-care settings, the MARS Bioimaging Extremity Scanner System delivers premium, high-resolution 3D X-ray images that visualize soft tissue, bone, blood vessels and metallic implants with clear material differentiation.

March 20, 2026 — Siemens Healthineers recently announced its Varian TrueBeam radiotherapy systems, which include TrueBeam, TrueBeam STx, VitalBeam and Edge, have received FDA 510(k) clearance for the use of low-dose radiation therapy (LDRT) in adults with medically refractory osteoarthritis (OA). This clearance expands Varian’s radiotherapy systems beyond cancer care into chronic musculoskeletal conditions, bringing precision radiotherapy to millions of people living with persistent pain and limited mobility.

March 18, 2026 — FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to FG001 as an intraoperative imaging agent to guide surgical resection of high-grade glioma.

U.S. FDA Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to patients earlier.

March 17, 2026 – OXOS Medical recently announced that its MC2 portable X-ray system is now cleared for pediatric imaging, enabling providers to deliver quality, low-dose X-ray imaging to young patients. 

Traditional imaging rooms can be intimidating for children¹ and stressful for parents².  MC2 changes the dynamic by making the exam and imaging room one and the same, meeting young patients where they are comfortable, close to their loved ones. 

March 2, 2026 — A collaborative modeling study found that adding biennial breast magnetic resonance imaging (MRI) to routine mammogram screening could avert more breast cancer deaths among women with extremely dense breasts and higher-than-average cancer risk.

If MRI costs and false-positive biopsy recommendations are reduced, supplemental MRI directed to high-risk women with dense breasts could show promise. The study is published in Annals of Internal Medicine.